Compare MakeMyTrip Ltd (MMYT) vs Pfizer Inc (PFE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
MakeMyTrip Ltd vs Pfizer Inc — how do they compare? MakeMyTrip Ltd trades at $44.52 (market cap $4.09B), while Pfizer Inc trades at $28.19 (market cap $158.56B). The key difference: Pfizer Inc is far larger — about 38.8× MakeMyTrip Ltd's market cap, and Pfizer Inc pays a 6.18% dividend while MakeMyTrip Ltd pays none. Which is the better fit depends on your goals — on Pluang, investors hold MakeMyTrip Ltd for 12 Days and Pfizer Inc for 158 Days on average.
| MMYT | PFE | |
|---|---|---|
Market Cap | $4.09B | $158.56B |
Volume | 1,828,010 | 44,138,282 |
Sector | Consumer Cyclical | Health |
52-Week High | $94.43 | $29.02 |
52-Week Low | $36.30 | $23.67 |
Typical Hold Time | 12 Days | 158 Days |
Enterprise Value | $4.75B | $210.06B |
Dividend Yield | — | 6.18% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MMYT trades at $44.33, up 2.12% today, but technical indicators signal a bearish trend. The company reported mixed quarterly earnings, with a Q1 2026 beat but Q4 2025 and Q2 2026 misses. Revenue grew to $978.34M in 2025, though net income margin remains thin at 3.23%. Analyst consensus is strongly bullish with a $77.00 price target, but institutional selling and a projected decline in 2026 cash flow pose concerns.
The stock presents a high-risk, high-reward opportunity. Strong analyst support and a potential Indian listing offer upside, but bearish technicals, earnings volatility, and rising debt-to-asset ratios in 2026 highlight significant risks. Investors should weigh the optimistic price targets against fundamental pressures and market sentiment.
Pfizer (PFE) trades at $28.00, up 1.87% on the day, with a bullish technical signal from moving averages. The company reported revenue of $62.58 billion in 2025 with a net income margin of 6.8%, and has beaten EPS estimates for the last three quarters. Recent news highlights Pfizer's focus on its obesity and oncology pipeline as key growth drivers in 2026.
The stock presents a value opportunity with a consensus price target of $29.17, but faces risks from patent expirations and projected earnings decline. Investor sentiment is mixed, with analysts largely neutral, emphasizing the stock's defensive cash flow and dividend yield amid ongoing business transformation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About MakeMyTrip Ltd
MakeMyTrip Ltd. is a leading online travel company in India, providing a comprehensive range of travel services and products, including air tickets, hotels, holiday packages, rail tickets, and bus tickets. The company operates its primary websites and mobile apps under the brands MakeMyTrip, Goibibo, and RedBus. MMYT serves as a key intermediary in India's fragmented travel market, leveraging its platform to offer convenience and competitive pricing to consumers and businesses.
Read more on MMYT →About Pfizer Inc
Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Read more on PFE →
